Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $20.83

by · The Markets Daily

Shares of Altimmune, Inc. (NASDAQ:ALT – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $20.83.

A number of research firms have recently weighed in on ALT. William Blair reissued a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. Stifel Nicolaus assumed coverage on Altimmune in a research report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Thursday, April 3rd.

Read Our Latest Research Report on ALT

Altimmune Stock Up 2.5 %

Shares of NASDAQ ALT opened at $4.97 on Thursday. The company has a market capitalization of $382.68 million, a PE ratio of -3.21 and a beta of 0.91. The stock’s 50 day moving average price is $5.32 and its 200-day moving average price is $6.70. Altimmune has a twelve month low of $3.55 and a twelve month high of $11.16.

Altimmune (NASDAQ:ALT – Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. As a group, research analysts expect that Altimmune will post -1.35 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Gregory L. Weaver bought 10,000 shares of the stock in a transaction on Thursday, March 13th. The shares were acquired at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the purchase, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at $52,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ALT. Virtu Financial LLC purchased a new position in Altimmune during the third quarter worth about $674,000. Barclays PLC grew its holdings in shares of Altimmune by 93.0% during the third quarter. Barclays PLC now owns 155,741 shares of the company’s stock worth $956,000 after purchasing an additional 75,064 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Altimmune by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after purchasing an additional 4,772 shares during the last quarter. Stifel Financial Corp raised its stake in Altimmune by 77.4% in the third quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock valued at $109,000 after purchasing an additional 7,746 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in Altimmune during the fourth quarter valued at approximately $45,000. Institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

(Get Free Report

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

Read More